Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Regen Biopharma Inc (RGBPP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 36-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0023 +121.74%
on 11/07/18
0.0135 -62.22%
on 11/13/18
-0.0039 (-43.33%)
since 10/16/18
3-Month
0.0023 +121.74%
on 11/07/18
0.0200 -74.50%
on 09/28/18
-0.0149 (-74.50%)
since 08/16/18
52-Week
0.0023 +121.74%
on 11/07/18
0.0900 -94.33%
on 11/21/17
-0.0399 (-88.67%)
since 11/16/17

Most Recent Stories

More News
Regen BioPharma, Inc. Reports Additional New NR2F6 Small Molecule Inhibitors

Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) researchers have identified three new series of small molecule drugs that inhibit NR2F6, bringing the total number of these series to five.

RGBP : 0.0046 (-4.17%)
RGBPP : 0.0051 (-16.39%)
Regen BioPharma, Inc. Determines Its Lead NR2F6 Agonist Ready for Inflammatory Bowel Disease Animal Studies

Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), reports its researchers have determined that its lead NR2F6 small molecule agonist, RG-NAH005, is now ready for testing in animal models of inflammatory...

RGBP : 0.0046 (-4.17%)
RGBPP : 0.0051 (-16.39%)
Regen BioPharma, Inc. Reports Activation of Immune Cells by Its NR2F6 Small Molecule Inhibitors

SAN DIEGO , September 21, 2018 /PRNewswire/ --

RGBP : 0.0046 (-4.17%)
RGBPP : 0.0051 (-16.39%)
Regen BioPharma, Inc. Reports Activation of Immune Cells by Its NR2F6 Small Molecule Inhibitors

Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), reports its researchers have identified a series of small molecule drugs that inhibit NR2F6 and also activate human immune cells ex-vivo. Evidence...

RGBP : 0.0046 (-4.17%)
RGBPP : 0.0051 (-16.39%)
Regen BioPharma, Inc. Updates Report on Success of Its NR2F6 Small Molecule Antagonist Screening Program for Treating Cancer

SAN DIEGO , September 11, 2018 /PRNewswire/ --

RGBP : 0.0046 (-4.17%)
RGBPP : 0.0051 (-16.39%)
Regen BioPharma, Inc. Files New Composition of Matter Patent Application Based on Its Successful Modulation of NR2F6 by Its Small Molecule Compounds

Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has filed a patent application covering composition of matter and methods of use related to molecules identified in its small molecule program that...

RGBP : 0.0046 (-4.17%)
RGBPP : 0.0051 (-16.39%)
Regen BioPharma, Inc. Reports Success of its NR2F6 Small Molecule Screening Program for Treating Autoimmune Diseases

Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), has identified a series of small molecule drugs that inhibit NR2F6. Regen's screening process demonstrated that its recently identified novel chemical...

RGBP : 0.0046 (-4.17%)
RGBPP : 0.0051 (-16.39%)
Entest Group, Inc. Declares Property Dividend of 3,000,000 Common Shares of Zander Therapeutics Inc.

On May 10, 2018, Entest Group, Inc. (OTC: ETNI) declared the distribution on a pro rata basis as a dividend in kind of 3,000,000 of the common shares of Zander Therapeutics, Inc., par value $0.0001, currently...

RGBP : 0.0046 (-4.17%)
RGBPP : 0.0051 (-16.39%)
ETNI : 0.0114 (-23.49%)
Regen BioPharma, Inc. Nears Completion of Optimizing its Lead NR2F6 Small Molecule Agonist

SAN DIEGO , March 21, 2018 /PRNewswire/ --

RGBP : 0.0046 (-4.17%)
RGBPP : 0.0051 (-16.39%)
Regen BioPharma, Inc. Nears Completion of Optimizing its Lead NR2F6 Small Molecule Agonist

Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has been methodically optimizing small molecules that bind to, and activate, the NR2F6 nuclear receptor. The process is close to completion, with the...

RGBP : 0.0046 (-4.17%)
RGBPP : 0.0051 (-16.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade RGBPP with:

Key Turning Points

2nd Resistance Point 0.0064
1st Resistance Point 0.0058
Last Price 0.0051
1st Support Level 0.0048
2nd Support Level 0.0044

See More

52-Week High 0.0900
Fibonacci 61.8% 0.0565
Fibonacci 50% 0.0462
Fibonacci 38.2% 0.0358
Last Price 0.0051
52-Week Low 0.0023

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar